Healio Transforming Glaucoma Care With Rho Kinase Inhibitors
Effective treatment of glaucoma is crucial to prevent vision loss and preserve quality of life in affected patients. This CME program explores the medical management of glaucoma using Rho kinase inhibitors (ROCKis) to lower intraocular pressure (IOP) and reduce episcleral venous pressure. Experts will review clinical and real-world data on ROCKi-based regimens, comparing monotherapy and combination approaches for IOP reduction. Clinical cases will illustrate the practical application of ROCKi in daily practice, exploring strategies to improve outcomes for patients with glaucoma.
Cost: Free
View Offer chevron_rightDetails
Effective treatment of glaucoma is crucial to prevent vision loss and preserve quality of life in affected patients. This CME program explores the medical management of glaucoma using Rho kinase inhibitors (ROCKis) to lower intraocular pressure (IOP) and reduce episcleral venous pressure. Experts will review clinical and real-world data on ROCKi-based regimens, comparing monotherapy and combination approaches for IOP reduction. Clinical cases will illustrate the practical application of ROCKi in daily practice, exploring strategies to improve outcomes for patients with glaucoma.
Topics Covered
Glaucoma Care With Rho Kinase Inhibitors
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Distinguish the mechanism of action of ROCKis from other classes of agents used to treat patients with glaucoma.
- Recognize the impact of ROCKis on IOP and episcleral venous pressure.
- Use real-world evidence for use of ROCKis as monotherapy or combination therapy in the treatment of patients with glaucoma.
Target Audience
The intended audience for this activity is comprehensive ophthalmologists involved in the management of patients with glaucoma.